source
- Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trialA recent study of a personalized mRNA cancer vaccine showed a 42% reduction in disease recurrence for patients with melanoma compared with the standard of care. The vaccine is tailored to each pat…
- AI drug developer Pathos secures $237 million Series E, valuation hits $3 billionPathos announced a $237 million Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The funding will support expansion beyond oncology into neurology, leveraging…